Syngene International Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cookgual9kowstrxxa05ui7h.pdf

Key Takeaways


Full-Year Performance

Hunt: "Strong growth in the fourth quarter, added to a positive performance over the course of the year, delivered full-year results ahead of our upgraded guidance."

Margin Walk


Manufacturing Services & Zoetis


Capacity & Infrastructure Build-Out


Client Partnerships & Longevity


Demand Environment & Outlook

Hunt: "Looking ahead, we are optimistic - despite challenges such as inflation, geopolitical uncertainties and recessionary pressures visible in some regions of the world - that our performance over the last year and the progress we have made on the strategic development of the Company, position us well for the year ahead."
Biswas: "As a result, in this fiscal year, the Company delivered the highest absolute year-on-year increase in revenue and EBITDA that we have seen in the last 5 years, providing a strong foundation for our future plans."

Guidance & Commitments

CommitmentSpecificsTimeline
Zoetis partnership valueUp to US$500 Mn over 10 years, subject to regulatory approvals and market demand10-year horizon
BMS collaborationExtended through end of 2030 with expanded drug discovery scopeThrough 2030
Dividend payout50 paisa/share ordinary + 75 paisa/share special dividend, subject to shareholder approvalAGM approval

Key Metrics

MetricQ4 FY23
Revenue from operations₹994 Cr, up 31% YoY
Total revenue₹1,017 Cr, up 32% YoY
Reported EBITDA₹337 Cr, up 27% YoY
EBITDA margin33.1%, down from 34.3% in Q4 FY22
PAT before exceptional item₹179 Cr, up 21% YoY
PAT margin17.6%, down from 19.1% in Q4 FY22
Full-year FY23 revenue from operations₹3,193 Cr, up 23% YoY
Full-year FY23 EBITDA margin30.8%, down from 31.9% in FY22
Full-year FY23 PAT before exceptional item₹464 Cr, up 10% YoY
Net cash₹224 Cr
Dividend per share50 paisa, plus special additional dividend of 75 paisa to mark 30th anniversary
Zoetis partnership valueUp to US$500 Mn over 10 years, subject to regulatory approvals and market demand
Scientists at Hyderabad facility~900
Total scientistsMore than 5,200
New jobs created during FY23Over 1,000